{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:34:58Z","timestamp":1789824898870,"version":"4.0.1"},"reference-count":38,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T00:00:00Z","timestamp":1427068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["HHSN272201000021I"],"award-info":[{"award-number":["HHSN272201000021I"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Adenovirus infections of immunocompromised pediatric hematopoietic stem  cell transplant patients can develop into serious and often deadly multi-organ disease. There are no drugs approved for adenovirus infections. Cidofovir (an analog of 2-deoxycytidine monophosphate) is used at times but it can be nephrotoxic and its efficacy has not been proven in clinical trials. Brincidofovir, a promising lipid-linked derivative of cidofovir, is in clinical trials. Ganciclovir, an analog of 2-deoxyguanosine, has been employed occasionally but with unknown efficacy in the clinic. In this study, we evaluated valganciclovir against disseminated adenovirus type 5 (Ad5) infection in our permissive immunosuppressed Syrian hamster model. We administered valganciclovir prophylactically, beginning 12 h pre-infection or therapeutically starting at Day 1, 2, 3, or 4 post-infection. Valganciclovir significantly increased survival, reduced viral replication in the liver, and mitigated the pathology associated with Ad5 infection. In cultured cells, valganciclovir inhibited Ad5 DNA replication and blocked the transition from early to late stage of infection. Valganciclovir directly inhibited Ad5 DNA polymerase in vitro, which may explain, at least in part, its mechanism of action. Ganciclovir and valganciclovir are approved to treat infections by certain herpesviruses. Our results support the use of valganciclovir to treat disseminated adenovirus infections in immunosuppressed patients.<\/jats:p>","DOI":"10.3390\/v7031409","type":"journal-article","created":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T12:17:00Z","timestamp":1427113020000},"page":"1409-1428","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Valganciclovir Inhibits Human Adenovirus Replication and Pathology in Permissive Immunosuppressed Female and Male Syrian Hamsters"],"prefix":"10.3390","volume":"7","author":[{"given":"Karoly","family":"Toth","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology,  Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoling","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology,  Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Tollefson","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology,  Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology,  Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-9559","authenticated-orcid":false,"given":"Lata","family":"Balakrishnan","sequence":"additional","affiliation":[{"name":"Department of Biology, Indiana University \u00ad Purdue University Indianapolis, Indianapolis,  IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sagartz","sequence":"additional","affiliation":[{"name":"Department of Comparative Medicine, Saint Louis University School of Medicine,  1100 S. Grand Blvd., St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Buller","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology,  Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wold","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology,  Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,3,23]]},"reference":[{"key":"ref_1","unstructured":"Knipe, D.M., and Howley, P.M. (2013). Fields Virology, Lippincott Williams & Wilkins."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/14787210.2013.836964","article-title":"Diagnosis and treatment of adenovirus infection in immunocompromised patients","volume":"11","author":"Boztug","year":"2013","journal-title":"Expert review of anti-infective therapy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/tid.12022","article-title":"European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: Summary of ECIL-4 (2011)","volume":"14","author":"Feuchtinger","year":"2012","journal-title":"Transplant infectious disease: An official journal of the Transplantation Society"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11908-014-0416-y","article-title":"Adenovirus: Current epidemiology and emerging approaches to prevention and treatment","volume":"16","author":"Sandkovsky","year":"2014","journal-title":"Current infectious disease reports"},{"key":"ref_6","first-page":"338","article-title":"Antiviral Agents","volume":"Vol. 1","author":"Knipe","year":"2013","journal-title":"Fields Virology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"Florescu","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcv.2010.10.016","article-title":"Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001","volume":"50","author":"Paolino","year":"2011","journal-title":"J. Clin. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2014.10.005","article-title":"Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model","volume":"112","author":"Tollefson","year":"2014","journal-title":"Antiviral Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.0800200105","article-title":"Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model","volume":"105","author":"Toth","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/JVI.02127-08","article-title":"Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters","volume":"83","author":"Dhar","year":"2009","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dhar, D., Toth, K., and Wold, W.S. M. (2014). Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Ther.","DOI":"10.1038\/cgt.2014.13"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/mt.2008.162","article-title":"Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model","volume":"16","author":"Thomas","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/cgt.2009.5","article-title":"An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector","volume":"16","author":"Lichtenstein","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/cgt.2009.6","article-title":"INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: Comparison of biodistribution studies","volume":"16","author":"Ying","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/CMR.00052-07","article-title":"Adenoviruses in immunocompromised hosts","volume":"21","author":"Echavarria","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/505498","article-title":"Adenovirus infections in transplant recipients","volume":"43","author":"Ison","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1128\/AAC.01311-07","article-title":"Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection","volume":"52","author":"Lenaerts","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1182\/blood-2010-04-259291","article-title":"How I treat adenovirus in hematopoietic stem cell transplant recipients","volume":"116","author":"Lindemans","year":"2010","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-6143.2007.02026.x","article-title":"A survey of CMV prevention strategies after liver transplantation","volume":"8","author":"Levitsky","year":"2008","journal-title":"American journal of transplantation: Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7","article-title":"Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2","volume":"89","author":"Sugawara","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0092-8674(87)90175-9","article-title":"Functional domains of adenovirus type 5 E1a proteins","volume":"50","author":"Lillie","year":"1987","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1128\/jcm.17.2.360-364.1983","article-title":"Adenovirus hexon monoclonal antibody that is group specific and potentially useful as a diagnostic reagent","volume":"17","author":"Cepko","year":"1983","journal-title":"J. Clin. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0092-8674(80)90362-1","article-title":"DNA replication and the early to late transition in adenovirus infection","volume":"22","author":"Thomas","year":"1980","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/jvi.22.2.527-539.1977","article-title":"Immunofluorescence study of the adenovirus type 2 single- stranded DNA binding protein in infected and transformed cells","volume":"22","author":"Sugawara","year":"1977","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/jvi.60.2.353-362.1986","article-title":"Identification of two nuclear subclasses of the adenovirus type 5-encoded DNA-binding protein","volume":"60","author":"Voelkerding","year":"1986","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/mt.2009.156","article-title":"Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model","volume":"17","author":"Dhar","year":"2009","journal-title":"Mol. Ther"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbmt.2003.11.001","article-title":"Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab","volume":"10","author":"Avivi","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_31","first-page":"295","article-title":"Adenovirus infection in a renal transplant patient","volume":"24","author":"Blohme","year":"1992","journal-title":"Transplant. Proc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1083-8791(03)00102-2","article-title":"Adenovirus infection in hematopoietic stem cell transplantation: Effect of ganciclovir and impact on survival","volume":"9","author":"Bruno","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1700997","article-title":"Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir","volume":"20","author":"Chen","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0002-9343(97)85997-9","article-title":"Treatment with ganciclovir of adenovirus pneumonia in a cardiac transplant patient","volume":"103","author":"Duggan","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev.Med.Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1590\/S0004-27492011000600007","article-title":"[Ganciclovir 0.15% ophthalmic gel in the treatment of adenovirus keratoconjunctivitis]","volume":"74","author":"Yabiku","year":"2011","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"American journal of transplantation: Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"ref_38","unstructured":"Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, Available online:www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm078932.pdf."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/3\/1409\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:43:49Z","timestamp":1760215429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/3\/1409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,23]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3]]}},"alternative-id":["v7031409"],"URL":"https:\/\/doi.org\/10.3390\/v7031409","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,23]]}}}